Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Phase 3

Terminated

• Conditions: Carcinoma, Non-Small Cell Lung

• Registration Number: NCT00243204
• Lead Sponsor: Point Therapeutics

Brief Summary

This Phase 3 study will compare the efficacy of talabostat plus docetaxel to docetaxel plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-10-19
• Study First Submitted QC: 2005-10-19
• Study First Posted: 2005-10-21
• Study Start: 2006-01
• Status Verified: 2007-06
• Last Update Submitted: 2007-06-07
• Last Update Posted: 2007-06-08

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (90)

Marshall Schreeder, MD; 🇺🇸 Huntsville, Alabama, United States

James P. Daugherty, MD; 🇺🇸 Muscle Shoals, Alabama, United States

Alaska Cancer Research; 🇺🇸 Anchorage, Alaska, United States

Hematology Oncology Associates; 🇺🇸 Phoenix, Arizona, United States

Veena Charu, MD; 🇺🇸 Anaheim, California, United States

Lalita Pandit, MD, Inc; 🇺🇸 Fountain Valley, California, United States

Robert A. Moss, MD, FACP, Inc.; 🇺🇸 Fountain Valley, California, United States

Warren Paroly, MD; 🇺🇸 Oceanside, California, United States

Swarna S. Chanduri, MD; 🇺🇸 Pomona, California, United States

Southwest Cancer Care Medical Group; 🇺🇸 Poway, California, United States

Scroll for more (80 remaining)